You are here: Industry Insights > biosimilar

News List

Teva enters biosimilar commercialisation partnership with Alvotech pharmaceutical-technology
August 06, 2020
Israel-based Teva Pharmaceutical has formed an exclusive strategic collaboration with Alvotech to commercialise five biosimilar candidates in the US.
Biocon and Mylan launch fulphila — biosimilar to pegfilgrastim, in Canada expresspharma
April 29, 2020
The approval of fulphila was based on a comprehensive package of analytical, non-clinical and clinical data, which confirmed that the product is highly similar to neulasta and no clinically meaningful differences in terms of safety and efficacy exist.
FDA transitions to new regulatory pathway for biosimilars europeanpharmaceuticalreview
March 25, 2020
The US FDA will now approve biosimilars via a new regulatory pathway to help grow the competition between biologic products.
Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada prnasia
January 15, 2020
Coherus plans to file a Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") in late 2020 or early 2021 depending on FDA interaction timing, and to launch directly upon approval.
The 2nd Chinese-Produced Adalimumab Biosimilar to be Approved for Marketing PharmaSources/Xiaoyaowan
January 08, 2020
From the current pattern in China, rather than the price war, Chinese-produced adalimumab biosimilars shall work on at least the following aspects: to strive to enter the NRDL to solve patients’ worries about payment; to strive for more indications to exp
Important Progresses of New Drugs Marketed in China in 2019 En-CPhI.CN
January 07, 2020
Imported Drugs:1、Novartis CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market Novartis f
WHO announces first biosimilar medicine pre-qualification europeanpharmaceuticalreview
January 03, 2020
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
Chinese Autoimmune Disease Drug Market: Which of the Competing Global Blockbuster Drugs Will Win? PharmaSources/1°C
December 05, 2019
Adalimumab has been “active” recently. Multiple adalimumab biosimilars are entering the harvest period in China following the arrival of China’s biosimilar era starting with ...
Breaking News! China’s Humira Biosimilar Produced by Bio-Thera to be Marketed Soon PharmaSources/Caicai
November 05, 2019
The marketing application of Bio-Thera’s adalimumab (acceptance No.: CXSS1800018) has recently been under the “under approval” status, which is expected to be approved for marketing soon for treating ankylosing spondylitis (AS).
Sandoz licences proposed multiple sclerosis biosimilar from Polpharma pharmaceutical-technology
September 04, 2019
Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizumab.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page